SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer
New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 a...
Gespeichert in:
Veröffentlicht in: | Journal of biochemical and molecular toxicology 2024-11, Vol.38 (11), p.e70018-n/a |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 11 |
container_start_page | e70018 |
container_title | Journal of biochemical and molecular toxicology |
container_volume | 38 |
creator | Yildiz, Baris Demirel, Ramazan Staudacher, Jonas J. Beseren, Hatice Yildiz, Gulden Akpinar, Ali Emre Park, Seong‐Hoon Ozden, Ozkan |
description | New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer.
SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells.
Highlights
Upregulation of FOXM1 may be an early molecular signal required for cancer
SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro
Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA
Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells |
doi_str_mv | 10.1002/jbt.70018 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3118305886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3118305886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2788-ad354f4aeedd3b677cd2e064e11b7c89c6cc6dc60b3dc7b56c7b8dae92bb18a63</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgipvTg19ACl700C1JmzQ96nBuogx0greQJm-xo2tn0qL79mbr9CB4yZ-XHw8vD0LnBA8JxnS0zJphgjERB6hPcJqGOObkcPdmIecJ7qET55YYY5Ym7Bj1ojSmLGZxH01fZs8LGhhQGppNqRpwgaqMH2gLyvlf8w4BfK0tOFfUVVDnwWT-9kSCogp0XfqJVpUGe4qOclU6ONvfA_Q6uVuMp-Hj_H42vnkMNU2ECJWJWJzHCsCYKONJog0FzGMgJEu0SDXXmhvNcRYZnWSM-0MYBSnNMiIUjwboqstd2_qjBdfIVeE0lKWqoG6djAgREWZCbOnlH7qsW1v57byiXAhCI-LVdae0rZ2zkMu1LVbKbiTBcluv9PXKXb3eXuwT22wF5lf-9OnBqAOfRQmb_5Pkw-2ii_wGSguCyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126881231</pqid></control><display><type>article</type><title>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yildiz, Baris ; Demirel, Ramazan ; Staudacher, Jonas J. ; Beseren, Hatice ; Yildiz, Gulden ; Akpinar, Ali Emre ; Park, Seong‐Hoon ; Ozden, Ozkan</creator><creatorcontrib>Yildiz, Baris ; Demirel, Ramazan ; Staudacher, Jonas J. ; Beseren, Hatice ; Yildiz, Gulden ; Akpinar, Ali Emre ; Park, Seong‐Hoon ; Ozden, Ozkan</creatorcontrib><description>New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer.
SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells.
Highlights
Upregulation of FOXM1 may be an early molecular signal required for cancer
SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro
Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA
Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells</description><identifier>ISSN: 1095-6670</identifier><identifier>ISSN: 1099-0461</identifier><identifier>EISSN: 1099-0461</identifier><identifier>DOI: 10.1002/jbt.70018</identifier><identifier>PMID: 39425454</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetylation ; Berberine ; Colon ; Colon cancer ; Colonic Neoplasms - genetics ; Colonic Neoplasms - metabolism ; Colonic Neoplasms - pathology ; Colorectal cancer ; Colorectal carcinoma ; CRC ; Deacetylation ; Disease management ; Female ; Forkhead Box Protein M1 - genetics ; Forkhead Box Protein M1 - metabolism ; FOXM1 ; Gene Expression Regulation, Neoplastic - drug effects ; HCT116 Cells ; Histones ; Humans ; Immunomodulation ; Immunoprecipitation ; Inhibitors ; Male ; Molecular interactions ; posttranslational regulation ; Quercetin ; Resveratrol ; SirReal2 ; sirtuin ; Sirtuin 2 - genetics ; Sirtuin 2 - metabolism ; Staining ; Therapeutic applications ; Tumor cell lines</subject><ispartof>Journal of biochemical and molecular toxicology, 2024-11, Vol.38 (11), p.e70018-n/a</ispartof><rights>2024 The Author(s). published by Wiley Periodicals LLC.</rights><rights>2024 The Author(s). Journal of Biochemical and Molecular Toxicology published by Wiley Periodicals LLC.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2788-ad354f4aeedd3b677cd2e064e11b7c89c6cc6dc60b3dc7b56c7b8dae92bb18a63</cites><orcidid>0000-0002-9467-3761</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbt.70018$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbt.70018$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39425454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yildiz, Baris</creatorcontrib><creatorcontrib>Demirel, Ramazan</creatorcontrib><creatorcontrib>Staudacher, Jonas J.</creatorcontrib><creatorcontrib>Beseren, Hatice</creatorcontrib><creatorcontrib>Yildiz, Gulden</creatorcontrib><creatorcontrib>Akpinar, Ali Emre</creatorcontrib><creatorcontrib>Park, Seong‐Hoon</creatorcontrib><creatorcontrib>Ozden, Ozkan</creatorcontrib><title>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</title><title>Journal of biochemical and molecular toxicology</title><addtitle>J Biochem Mol Toxicol</addtitle><description>New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer.
SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells.
Highlights
Upregulation of FOXM1 may be an early molecular signal required for cancer
SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro
Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA
Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells</description><subject>Acetylation</subject><subject>Berberine</subject><subject>Colon</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - metabolism</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>CRC</subject><subject>Deacetylation</subject><subject>Disease management</subject><subject>Female</subject><subject>Forkhead Box Protein M1 - genetics</subject><subject>Forkhead Box Protein M1 - metabolism</subject><subject>FOXM1</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>HCT116 Cells</subject><subject>Histones</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Immunoprecipitation</subject><subject>Inhibitors</subject><subject>Male</subject><subject>Molecular interactions</subject><subject>posttranslational regulation</subject><subject>Quercetin</subject><subject>Resveratrol</subject><subject>SirReal2</subject><subject>sirtuin</subject><subject>Sirtuin 2 - genetics</subject><subject>Sirtuin 2 - metabolism</subject><subject>Staining</subject><subject>Therapeutic applications</subject><subject>Tumor cell lines</subject><issn>1095-6670</issn><issn>1099-0461</issn><issn>1099-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10E9LwzAYBvAgipvTg19ACl700C1JmzQ96nBuogx0greQJm-xo2tn0qL79mbr9CB4yZ-XHw8vD0LnBA8JxnS0zJphgjERB6hPcJqGOObkcPdmIecJ7qET55YYY5Ym7Bj1ojSmLGZxH01fZs8LGhhQGppNqRpwgaqMH2gLyvlf8w4BfK0tOFfUVVDnwWT-9kSCogp0XfqJVpUGe4qOclU6ONvfA_Q6uVuMp-Hj_H42vnkMNU2ECJWJWJzHCsCYKONJog0FzGMgJEu0SDXXmhvNcRYZnWSM-0MYBSnNMiIUjwboqstd2_qjBdfIVeE0lKWqoG6djAgREWZCbOnlH7qsW1v57byiXAhCI-LVdae0rZ2zkMu1LVbKbiTBcluv9PXKXb3eXuwT22wF5lf-9OnBqAOfRQmb_5Pkw-2ii_wGSguCyw</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Yildiz, Baris</creator><creator>Demirel, Ramazan</creator><creator>Staudacher, Jonas J.</creator><creator>Beseren, Hatice</creator><creator>Yildiz, Gulden</creator><creator>Akpinar, Ali Emre</creator><creator>Park, Seong‐Hoon</creator><creator>Ozden, Ozkan</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9467-3761</orcidid></search><sort><creationdate>202411</creationdate><title>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</title><author>Yildiz, Baris ; Demirel, Ramazan ; Staudacher, Jonas J. ; Beseren, Hatice ; Yildiz, Gulden ; Akpinar, Ali Emre ; Park, Seong‐Hoon ; Ozden, Ozkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2788-ad354f4aeedd3b677cd2e064e11b7c89c6cc6dc60b3dc7b56c7b8dae92bb18a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acetylation</topic><topic>Berberine</topic><topic>Colon</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - metabolism</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>CRC</topic><topic>Deacetylation</topic><topic>Disease management</topic><topic>Female</topic><topic>Forkhead Box Protein M1 - genetics</topic><topic>Forkhead Box Protein M1 - metabolism</topic><topic>FOXM1</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>HCT116 Cells</topic><topic>Histones</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Immunoprecipitation</topic><topic>Inhibitors</topic><topic>Male</topic><topic>Molecular interactions</topic><topic>posttranslational regulation</topic><topic>Quercetin</topic><topic>Resveratrol</topic><topic>SirReal2</topic><topic>sirtuin</topic><topic>Sirtuin 2 - genetics</topic><topic>Sirtuin 2 - metabolism</topic><topic>Staining</topic><topic>Therapeutic applications</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yildiz, Baris</creatorcontrib><creatorcontrib>Demirel, Ramazan</creatorcontrib><creatorcontrib>Staudacher, Jonas J.</creatorcontrib><creatorcontrib>Beseren, Hatice</creatorcontrib><creatorcontrib>Yildiz, Gulden</creatorcontrib><creatorcontrib>Akpinar, Ali Emre</creatorcontrib><creatorcontrib>Park, Seong‐Hoon</creatorcontrib><creatorcontrib>Ozden, Ozkan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biochemical and molecular toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yildiz, Baris</au><au>Demirel, Ramazan</au><au>Staudacher, Jonas J.</au><au>Beseren, Hatice</au><au>Yildiz, Gulden</au><au>Akpinar, Ali Emre</au><au>Park, Seong‐Hoon</au><au>Ozden, Ozkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer</atitle><jtitle>Journal of biochemical and molecular toxicology</jtitle><addtitle>J Biochem Mol Toxicol</addtitle><date>2024-11</date><risdate>2024</risdate><volume>38</volume><issue>11</issue><spage>e70018</spage><epage>n/a</epage><pages>e70018-n/a</pages><issn>1095-6670</issn><issn>1099-0461</issn><eissn>1099-0461</eissn><abstract>New FOXM1‐specific inhibitors with the potential to be used for therapeutic purposes are under extensive research. We hypothesized that deacetylation of FOXM1 would decrease protein expression, thus providing novel therapeutic management of colon cancers. Immunostaining was used to determine FOXM1 and SIRT2 expressions in human colon cancer tissue microarrays (n = 90) from Stage I to Stage IV. SIRT2‐FOXM1 interaction was evaluated in colon cancer cells using immunoprecipitation. Deacetylation of FOXM1 via SIRT2 was determined using in vitro deacetylation assays. FOXM1 could be hyper‐acetylated when p300 and pCAF histone acetyltransferases were administered alongside deacetylase inhibitors. We detected that SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro. SIRT2 overexpression led to a significant decrease while knockdown of SIRT2 increased the FOXM1 expression in HCT116 human colon carcinoma cells. In the analysis of 90 human colorectal cancer samples, high SIRT2 expression was observed in about 49% of colorectal cancer, intermediate in 29%, and low or no staining in 22%. Strong SIRT2 expression was found to be negatively associated with the FOXM1 staining in our clinical cohort. This study reveals a molecular interaction and association between SIRT2 and FOXM1 expression in colon cancer cell lines and human colon cancer samples, and suggests that targeting SIRT2 activity using small molecule modulators may be a promising therapeutic approach for colorectal cancer.
SIRT2‐FOXM1 interaction in colon cancer. SIRT2 and FOXM1 physically interacted and SIRT2 deacetylated FOXM1 in vitro. Strong SIRT2 expression was negatively associated with FOXM1 staining in a human colon carcinoma tissue microarray. Resveratrol, berberine, and quercetin reduced FOXM1 expression in colon cancer cells.
Highlights
Upregulation of FOXM1 may be an early molecular signal required for cancer
SIRT2 and FOXM1 physically interacted, and SIRT2 deacetylated FOXM1 in vitro
Strong SIRT2 expression was negatively associated with the FOXM1 staining in the TMA
Resveratrol, berberine and quercetin decreased FOXM1 expression in colorectal cancer cells</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39425454</pmid><doi>10.1002/jbt.70018</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9467-3761</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1095-6670 |
ispartof | Journal of biochemical and molecular toxicology, 2024-11, Vol.38 (11), p.e70018-n/a |
issn | 1095-6670 1099-0461 1099-0461 |
language | eng |
recordid | cdi_proquest_miscellaneous_3118305886 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Acetylation Berberine Colon Colon cancer Colonic Neoplasms - genetics Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Colorectal cancer Colorectal carcinoma CRC Deacetylation Disease management Female Forkhead Box Protein M1 - genetics Forkhead Box Protein M1 - metabolism FOXM1 Gene Expression Regulation, Neoplastic - drug effects HCT116 Cells Histones Humans Immunomodulation Immunoprecipitation Inhibitors Male Molecular interactions posttranslational regulation Quercetin Resveratrol SirReal2 sirtuin Sirtuin 2 - genetics Sirtuin 2 - metabolism Staining Therapeutic applications Tumor cell lines |
title | SIRT2 deacetylates and decreases the expression of FOXM1 in colon cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SIRT2%20deacetylates%20and%20decreases%20the%20expression%20of%20FOXM1%20in%20colon%20cancer&rft.jtitle=Journal%20of%20biochemical%20and%20molecular%20toxicology&rft.au=Yildiz,%20Baris&rft.date=2024-11&rft.volume=38&rft.issue=11&rft.spage=e70018&rft.epage=n/a&rft.pages=e70018-n/a&rft.issn=1095-6670&rft.eissn=1099-0461&rft_id=info:doi/10.1002/jbt.70018&rft_dat=%3Cproquest_cross%3E3118305886%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3126881231&rft_id=info:pmid/39425454&rfr_iscdi=true |